Table 2.
Baseline characteristics of participants in the ASPIRE trial (Aug 2012–Jun 2015) who completed acceptability measures at month-3 and/or PUEV
| Total | ||
|---|---|---|
| N | (%) | |
| Total | 2562 | (100) |
| Age, years—mean, median (IQR) | 27.2, 26 | (22–31) |
| 18–21 | 507 | (20) |
| 22–45 | 2055 | (80) |
| Completed secondary school | 1172 | (46) |
| Earns own income | 1156 | (45) |
| Has primary sex partner | 2496 | (98) |
| Currently married | 1058 | (41) |
| ≥ 2 male sex partners in past 3 mo | 1489 | (58) |
| Transactional sex in past year | 156 | (6) |
| Parity > 0 | 2350 | (92) |
| Current contraceptive method | ||
| Injectable | 1407 | (55) |
| Implant | 494 | (19) |
| Intrauterine device (IUD) | 319 | (13) |
| Oral contraceptive pills | 278 | (11) |
| Male condoms | 94 | (4) |
| Sterilizationa | 77 | (3) |
PUEV product use end visit, IQR interquartile range
aTubal ligation/hysterectomy/laparoscopy/other surgical procedure that causes sterilization